MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Growing Patient Demand for GLP-1 Medications

Formulations to be marketed as Slim and Trim as an orally dissolvable tablet (ODT)

Dallas, TX, May 21, 2024 (GLOBE NEWSWIRE) — Mangoceuticals, Inc. (NASDAQ: MGRX) (MangoRx or the Company), a company focused on developing, marketing and selling a variety of men’s health and wellness products in the areas of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce the development of oral proprietary formulations of Semaglutide (Slim) and Tirzepatide (Trim) to aid in weight management. These innovative drugs, currently available mainly in injectable form, have demonstrated remarkable efficacy in clinical trials. MangoRxs new oral formulations are poised to revolutionize the weight loss market and capture a significant market share.

The market for GLP-1 receptor agonists, including Semaglutide and Tirzepatide, is projected to reach over $164 billion in combined revenue by 2032, based on Visible Alpha consensus, growing from $37.9 billion in 2023. These are record revenues for any drug class in the history of drug development.

Oral formulations of Semaglutide and Tirzepatide are set to capture a significant portion of this market, providing a convenient alternative to injections. Semaglutide, marketed under the brand names Ozempic ^{and Wegovyand Tirzepatide, marketed as Mounjaro and Zepbound, are both glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs have demonstrated impressive weight loss results in clinical trials. In a recent study, patients taking Semaglutide achieved an average weight loss of 15.2% over one year, while those taking Tirzepatide experienced an average weight loss of 15.7%. Oral formulations of Semaglutide and Tirzepatide are designed for daily consumption and are expected to provide similar weight loss benefits without the need for regular injections.}

Studies of patient preferences consistently show a significant majority in favor of oral medications compared to injections. This preference is expected to drive higher adoption rates and expand the existing market. Switching to an oral formulation provides a more accessible and convenient option for patients, potentially increasing adherence and overall treatment success.

We are excited to introduce Slim and Trim, MangoRxs oral formulations of Semaglutide and Tirzepatide, to the weight loss market, said Jacob Cohen, CEO and Co-Founder of MangoRx. Our goal is to provide patients with a convenient and effective way to manage their weight and improve their overall health. We believe that these oral formulations have the potential to significantly impact the lives of millions of people worldwide.

The story continues

MangoRx plans to have the products available to customers on the company’s telemedicine platform in early 3.^st quarter with Slim and Trim competitively priced at $299/month and $399/month, respectively. MangoRx is dedicated to advancing the treatment of obesity and related conditions and is committed to improving the lives of patients worldwide.

About MangoRx

MangoRx is focused on developing a variety of products and services for men’s health and wellness through a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and particularly related to the field of erectile dysfunction (ED), hair growth and hormone replacement therapies. Interested customers can use the MangoRxs telemedicine platform for a seamless experience. Prescription requests will be reviewed by a physician and, if approved, will be discreetly filled and shipped through MangoRxs partner compounding pharmacy and straight to patients’ doorsteps. To learn more about MangoRxs mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including the meaning of the Private Securities Litigation Reform Act of 1995 (forward-looking statements). These forward-looking statements represent the Company’s current expectations or beliefs about future events and can generally be identified by using statements that include words such as estimate, expect, project, believe, predict, target, plan, anticipate, predict, have likely, will, intend or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are beyond the Company’s control, which could cause actual results to differ materially from those expressed or implied in the forward-looking statements, our ability to meet Nasdaq’s minimum bid price requirements; the Company’s stockholders’ equity at the end of the Company’s next fiscal quarter; our ability to maintain the listing of our common stock on Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain the Comis Federal para la Proteccin contra Riesgos Sanitarios for our ED product in Mexico, its costs and the timing associated therewith; our ability to obtain additional funding and generate revenue to support our operations; risks associated with our ED product, which have not been and will not be approved by the US Food and Drug Administration (FDA) and have not had the benefit of the FDA’s clinical trial protocol, which is intended to prevent the possibility of serious patient harm and death; risks that the FDA may determine that the composition of our planned products does not fall within an exemption from the Federal Food, Drug, and Cosmetic Act (The FFDCA Act) provided by article 503A; risks related to relationships and agreements with related parties; the effect of data security breaches, malicious code and/or hackers; our competition and ability to establish a recognized brand; changes in consumer tastes and preferences; material changes and/or termination of our relationships with key parties; significant customer product returns, product liabilities, recalls and litigation related to contaminated products or products found to cause health problems; our ability to innovate, expand our offerings and compete against competitors who may have greater resources; our significant reliance on related party transactions; the anticipated size of the potential market for our technologies and products; the risks associated with the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen, has significant voting control over the Company; risks related to the substantial number of shares outstanding, the volume of our shares, the effect of sales of a substantial number of shares in the market and the fact that most of our stockholders paid less for their shares than the public offering price. of our common stock in our most recent initial public offering; dilution caused by recent offerings; conversion of outstanding shares of preferred stock and their rights and preferences, the fact that we have a substantial number of outstanding warrants to purchase shares of common stock at $1.00 per share, the resale of which underlying shares are registered under the Securities Act of 1933, as amended; our ability to build and maintain our brand; cyber security, information systems and fraud risks and issues with our websites; changes in and our compliance with rules and regulations affecting our operations, sales, marketing and/or products; shipping, manufacturing or production delays; the regulations with which we are required to comply with respect to our operations, production, labeling and transportation; our dependence on third parties to prescribe and compound our ED product; our ability to establish or maintain relationships and/or relationships with third parties; potential safety risks associated with our Mango ED product, including the use of ingredients, the combination of these ingredients and their dosages; the effects of changing inflation rates and interest rates, and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russia conflict and the in Israel) and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; overdraft which could reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect customers’ levels of discretionary purchases of the Company’s products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected or suggested by the forward-looking statements we make in this release are reasonable, we give no assurance that these plans, intentions or expectations will be achieved. Accordingly, you should not consider such a list to be a complete set of all possible risks and uncertainties.

More information on potential factors that could affect the Company’s financial results is included from time to time in the Cautionary Note Regarding Forward-Looking Statements, Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s filings in SEC. , including the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the three months ended March 31, 2024. These filings are available at www.sec.gov and on our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributed to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the foregoing cautionary statements. Other unknown or unpredictable factors may also have a material adverse effect on the Company’s future results. The forward-looking statements contained in this press release are made only as of the date hereof. The Company cannot guarantee future results, activity levels, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company does not undertake to update these statements after the date of this publication, except as required by law, and assumes no obligation to update or correct information prepared by third parties that have not been paid by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Follow Mangoceuticals and MangoRx on social media:
https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial

FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com

SOURCE: Mangoceuticals Inc.